Davide Capodanno

Davide Capodanno

Interventional cardiologist / Cardiologist
Ferrarotto Hospital, University of Catania - Catania, Italy

Latest contributions

PCRonline has a new Editor-in-Chief!

15 Dec 2017

An associate professor at the University of Catania, where he received his MD and PhD degrees, and an interventional cardiologist at Ferrarotto Hospital, Azienda “Policlinico-Vittorio Emanuele” in Catania, Italy, Dr Capodanno completed his research training at the University of Florida, Jacksonville, FL, USA. His areas of interest and expertise include coronary revascularisation, drug-eluting stents and scaffold technologies, antithrombotic pharmacotherapy, trial design and biostatistics.

SPOTLIGHT: Standardised definitions for clinical and imaging endpoints after surgical and transcatheter valve intervention

In this presentation from PCR London Valves 2017, A. Baumbach, D. Capodanno, A. Lansky, M.B. Leon and N. Piazza focus on the durability, structural deterioration and valve failure, the neurological adverse events and on what really matters in clinical and patient-reported endpoints after surgical and transcatheter valve interventions.

SENIOR, DAPT-STEMI and REDUCE: TCT 2017 Late Breaking Trial Results

01 Nov 2017

Three trials focused on important discussion points for daily practice on the third day of TCT 2017, with two clinical questions in the spotlight: 1) is there still a niche for bare metal stents (BMS) in elderly patients? 2) Is a 12-month duration of DAPT a must-have for all acute coronary syndrome (ACS) patients in the current era?
 

CULPRIT-SHOCK, EXCEL and DKCRUSH-V: TCT 2017 Late Breaking Trial Results

30 Oct 2017

Two potentially impactful clinical trials were in the limelight during day 2 of TCT 2017, as well as the quality of life analysis of a trial comparing revascularization strategies for left main disease. Let’s take a look at the results and see what their potential could be for daily practice.

PCR @ TCT 2017

We will be covering a selection of major Late-breaking Clinical Trials in Interventional Cardiology to be released at the 2017 Transcatheter Cardiovascular Therapeutics Scientific Sessions. Get the European Perspective!

Case-based learning for the Heart Valve Team: direct percutaneous mitral annuloplasty

26 Sep 2017 – From PCR London Valves 2017

Late-breaking TAVI trials

25 Sep 2017 – From PCR London Valves 2017

Introduction to the PCR London Valves 2017 Aortic track - The key questions in TAVI: where are we in 2017?

25 Sep 2017 – From PCR London Valves 2017

VALIDATE-SWEDEHEART, TROPICAL-ACS and RE-DUAL PCI: Antithrombotic Therapy takes the stage

In the accompanying editorial of COMPASS, presented at the ESC Congress 2017 in Barcelona, Eugene Braunwald vividly referred to the field of “Thrombocardiology”. Indeed, the topic of antithrombotic pharmacotherapy is now broader than ever, with plenty of drugs, indications, strategies and clinical data. Three new trials (with simultaneous publications in the New England Journal of Medicine and in The Lancet) clarify doubts, inform clinical practice and open new questions.

Ticagrelor or clopidogrel in DAPT for acute coronary syndromes: A call for a stepwise approach?

Better stents, IVUS, FFR, medical therapy…or the integration of all? The SYNTAX-II trial

27 Aug 2017

CANTOS and COMPASS: New Avenues for Secondary Cardiovascular Prevention

27 Aug 2017

Two large trials dominated Sunday’s discussions at the ESC Congress 2017 in Barcelona. CANTOS and COMPASS met their respective primary endpoints, although this came as no surprise because topline results were already in the public domain due to press releases earlier this year. Yet presentation of the complete results, along with simultaneous publications in the New England Journal of Medicine, tell us the full story and gives us important novel information to digest.

PCR @ ESC Congress 2017

We will be providing live updates on a selection of major Late Breaking Scientific Sessions of interest to Interventional Cardiologists during ESC Congress 2017.

Individualising antiplatelet therapy after coronary interventions: a case-based focus on today's practice and perspectives

17 May 2017 – From EuroPCR 2017

Bioresorbable scaffold thrombosis: what have we learnt?

16 May 2017 – From EuroPCR 2017

Consult this session about what have we learnt about bioresorbable scaffold thrombosis presented by D. Capodanno, M. Joner, T. F. Lüscher, Y. Onuma, P. Serruys and N. West. Review incidence and predictors of bioresorbable scaffold thrombosis and gain insights about the mechanism underlying scaffold thrombosis and ongoing treatment.

Bioprosthetic valve leaflet thickening and long-term durability

16 May 2017 – From EuroPCR 2017

Consult this session on bioprosthetic valve leaflet thickening and long-term durability from EuroPCR 2017 if you want to find more about mechanisms of bioprosthetic valve failure and definitions of valve durability and clinical data concerning the long-term outcomes after TAVI.

Stents or scaffolds: relevant options for optimal patient outcomes?

16 May 2017 – From EuroPCR 2017

Late-breaking trials and trial updates

16 May 2017 – From EuroPCR 2017

Davide Capodanno

Chairperson

Davide Capodanno
William Wijns

Chairperson

William Wijns

Clinical research

15 May 2017 – From EuroPCR 2017

ABSORB III at 2 years: more events, more difference

19 Mar 2017

ABSORB III presented at ACC consolidate the understanding that bioresorbable scaffolds carry a higher risk of target lesion failure compared with their metallic counterpart

DECISION-CTO: the jury is still out

19 Mar 2017

A trial from South Korea was stopped prematurely due to slow recruitment, leaving unsolved the important clinical question under investigation.

iFR, the new gold standard? DEFINE-FLAIR and iFR-SWEDEHEART

19 Mar 2017

Two important trials have officially opened the evidence-based era of iFR.

Primary PCI is done: what about the rest? COMPARE ACUTE

19 Mar 2017

The session - entirely devoted to interventional cardiology – started with COMPARE ACUTE, a trial of FFR-guided complete revascularization beyond the culprit lesion in patients with STEMI.

FOURIER: Is evolocumab worth the cost?

18 Mar 2017

ACC.17 Late breaking clinical trial: Primary results of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial

SURTAVI: Should TAVI become class I for intermediate-risk patients with severe aortic stenosis?

18 Mar 2017

ACC.17 Late breaking clinical trial:  Transcatheter Aortic Valve Replacement with a self-expanding bioprothesis compared with surgical aortic valve replacement in patients at intermediate surgical risk: first results from the SURTAVI clinical trial Michael REARDON, Houston

Interactive Case Corner 3

14 Dec 2016 – From GulfPCR-GIM 2016

Focus on the best use of antiplatelets and antithrombotics post-PCI

23 Jan 2015 – From AsiaPCR/SingLIVE 2015

Prof. Eric Eeckhout

Chairperson

Eric Eeckhout
Dr. Soo Teik Lim

Chairperson

Soo Teik Lim

Spotlight session: bioprosthetic valve durability

19 Sep 2016 – From PCR London Valves 2016

Consult the session video, which sheds the spotlight on bioprosthetic valve durability.

Dr Bernard Prendergast

Chairperson

Bernard Prendergast
Prof. Stefan Windecker

Chairperson

Stephan Windecker

Will ABSORB III change my practice?

18 May 2016 – From EuroPCR 2016

Prof. Andreas Baumbach

Chairperson

Andreas Baumbach
Corrado Tamburino

Chairperson

Corrado Tamburino

Late breaking - Clinical research in interventional cardiology from a multidisciplinary perspective

22 May 2015 – From EuroPCR 2015

Lene Kloevgaard

Chairperson

Lene Kloevgaard